RGRodolfo Gustavo Goya

Rodolfo Gustavo Goya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rodolfo Gustavo Goya has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Mireille Dardenne

    CNRS UMR 8147, Université Paris Descartes, Hôpital Necker, Paris, France

    6 shared publications
  • Gustavo R. Morel

    Institute for Biochemical Research at La Plata (INIBIOLP)-Histology B, Faculty of Medicine, National University of La Plata, La Plata, Argentina

    4 shared publications
  • Gloria M. Cónsole

    Histology B-CICPBA, Faculty of Medicine, National University of La Plata (UNLP), La Plata, Argentina

    3 shared publications
  • Oscar A. Brown

    Institute for Biochemical Research, Faculty of Medicine, CONICET, National University of La Plata, La Plata, Argentina

    3 shared publications
  • Paula C. Reggiani

    Institute for Biochemical Research, and Histology B-CICPBA, Faculty of Medicine, National University of La Plata (UNLP), La Plata, Argentina

    3 shared publications
  • Yolanda E. Sosa

    Instituto de Investigaciones Bioquimicas de La Plata-Histology B-Comision de Investigaciones Cientificas de la Provincia de Buenos Aires, Facultad de Medicas, Universidad Nacional de La Plata, La Plata, Argentina

    3 shared publications

Latest Publications

  • Open Access

    Thymulin-Based Gene Therapy and Pituitary Function in Animal Models of Aging

    by Paula C. Reggiani, Brenda Poch, Gloria M. Cónsole, Omar J. Rimoldi, Jose I. Schwerdt, Victoria Tüngler, Margarita M. Garcia-Bravo, Mireille Dardenne, Rodolfo G. Goya

    Thymulin is a thymic hormone exclusively produced by the thymic epithelial cells. After its discovery and initial characterization in the 1970s, it was demonstrated that thymulin production and secretion is strongly influenced by the neuroendocrine system. Conversely, a growing core of information, to be reviewed here, points to thymulin as a hypophysiotropic peptide. Additionally, thymulin was shown to possess anti-inflammatory and analgesic properties in the brain. In recent years, a synthetic DNA sequence coding for a biologically active analog of thymulin, metFTS, was constructed and cloned in different adenoviral vectors. These include bidirectional regulatable Tet-Off vector systems that simultaneously express metFTS and green fluorescent protein and that can be downregulated reversibly by the addition of the antibiotic doxycycline. A number of recent studies suggest that thymulin gene therapy may be a suitable therapeutic strategy to prevent some of the endocrine and reproductive alterations that typically appear in congenitally athymic (nude) mice, taken as a suitable model of neuroendocrine and reproductive aging. The present article briefly reviews the literature on the physiology of the thymulin-pituitary axis as well as on the new molecular tools available to exploit the therapeutic potential of thymulin.


  • Glial cell line-derived neurotrophic factor gene therapy ameliorates chronic hyperprolactinemia in senile rats

    by G.R. Morel, Y.E. Sosa, M.J. Bellini, N.G. Carri, S.S. Rodriguez, M.C. Bohn, R.G. Goya


  • Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage

    by Gustavo R. Morel, Rubén W. Carón, Gloria M. Cónsole, Marta Soaje, Yolanda E. Sosa, Silvia S. Rodríguez, Graciela A. Jahn, Rodolfo G. Goya


  • The ependymal route for insulin-like growth factor-1 gene therapy in the brain

    by C.B. Hereñú, W.E. Sonntag, G.R. Morel, E.L. Portiansky, R.G. Goya


  • The Thymus–Neuroendocrine Axis

    by Paula C. Reggiani, Gustavo R. Morel, Gloria M. Cónsole, Claudio G. Barbeito, Silvia S. Rodriguez, Oscar A. Brown, Maria Jose Bellini, Jean‐Marie Pléau, Mireille Dardenne, Rodolfo G. Goya

    Thymulin is a thymic hormone exclusively produced by the thymic epithelial cells. It consists of a nonapeptide component coupled to the ion zinc, which confers biological activity to the molecule. After its discovery in the early 1970s, thymulin was characterized as a thymic hormone involved in several aspects of intrathymic and extrathymic T cell differentiation. Subsequently, it was demonstrated that thymulin production and secretion is strongly influenced by the neuroendocrine system. Conversely, a growing core of information, to be reviewed here, points to thymulin as a hypophysotropic peptide. In recent years, interest has arisen in the potential use of thymulin as a therapeutic agent. Thymulin was shown to possess anti‐inflammatory and analgesic properties in the brain. Furthermore, an adenoviral vector harboring a synthetic gene for thymulin, stereotaxically injected in the rat brain, achieved a much longer expression than the adenovirally mediated expression in the brain of other genes, thus suggesting that an anti‐inflammatory activity of thymulin prevents the immune system from destroying virus‐transduced brain cells. Other studies suggest that thymulin gene therapy may also be a suitable therapeutic strategy to prevent some of the endocrine and metabolic alterations that typically appear in thymus‐deficient animal models. The present article briefly reviews the literature on the physiology, molecular biology, and therapeutic potential of thymulin.


  • Open Access

    Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas

    by Gloria M Console, Claudia B Herenu, Gisela A Camihort, Georgina C Luna, Maria I Bracamonte, Gustavo R Morel, Rodolfo G Goya

    The implementation of gene therapy for the treatment of pituitary tumors emerges as a promising complement to surgery and may have distinct advantages over radiotherapy for this type of tumors. Up to now, suicide gene therapy has been the main experimental approach explored to treat experimental pituitary tumors. In the present study we assessed the effectiveness of insulin-like growth factor I (IGF-I) gene therapy for the treatment of estrogen-induced prolactinomas in rats.


  • Thymulin gene therapy prevents the reduction in circulating gonadotropins induced by thymulin deficiency in mice

    by Rodolfo G. Goya, Paula C. Reggiani, Silvan M. Vesenbeckh, Jean M. Pléau, Yolanda E. Sosa, Gloria M. Cónsole, Rüdiger Schade, Peter Henklein, Mireille Dardenne

    Integrity of the thymus during perinatal life is necessary for a proper maturation of the pituitary-gonadal axis in mice and other mammalian species. Thus congenitally athymic (nude) female mice show significantly reduced levels of circulating gonadotropins, a fact that seems to be causally related to a number of reproductive derangements described in these mutants. Interestingly, a number of in vitro studies suggest that the thymic peptide thymulin may be involved in thymus-pituitary communication. To determine the consequences of low serum thymulin in otherwise normal animals, we induced short (8 days)- and long (33 days)-term thymulin deficiency in C57BL/6 mice by neonatally injecting (intraperitoneally) an anti-thymulin serum and assessed their circulating gonadotropin levels at puberty and thereafter. Control mice received an irrelevant antiserum. Gonadotropins were measured by radioimmunoassay and thymulin by bioassay. Both long- and short-term serum thymulin immunoneutralization resulted in a significant reduction in the serum levels of gonadotropins at 33 and 45 days of age. Subsequently, we injected (intramuscularly) an adenoviral vector harboring a synthetic DNA sequence (5′-ATGCAAGCCAAATCTCAAGGTGGATCCAACTAGTAG-3′) encoding a biologically active analog of thymulin, methionine-FTS, in newborn nude mice (which are thymulin deficient) and measured circulating gonadotropin levels when the animals reached 52 days of age. It was observed that neonatal thymulin gene therapy in the athymic mice restored their serum thymulin levels and prevented the reduction in circulating gonadotropin levels that typically emerges in these mutants after puberty. Our results indicate that thymulin plays a relevant physiological role in the thymus-pituitary-gonadal axis.


  • Open Access

    PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes

    by Carolina Cristina, Graciela S Díaz-Torga, Rodolfo G Goya, Sham S Kakar, María I Perez-Millán, Vanessa Q Passos, Daniel Giannella-Neto, Marcello D Bronstein, Damasia Becu-Villalobos

    Background Pituitary tumor transforming gene (pttg) is a novel oncogene that is expressed at higher level in most of the tumors analyzed to date compared to normal tissues. Nevertheless, its expression in prolactinomas and its relation with the pituitary dopamine receptor 2 (D2R) are not well defined. We sought to determine the pituitary level of pttg in three different experimental models of prolactinomas with altered dopaminergic control of the pituitary: the dopaminergic D2R knockout female mouse, the estrogen-treated rat, and the senescent female rat. These three models shared the characteristics of increased pituitary weight, hyperprolactinemia, lactotrope hyperplasia and reduced or absent dopaminergic action at the pituitary level. We also studied samples from human macroprolactinomas, which were characterized as responsive or resistant to dopamine agonist therapy. Results When compared to female wild-type mice, pituitaries from female D2R knockout mice had decreased PTTG concentration, while no difference in pttg mRNA level was found. In senescent rats no difference in pituitary PTTG protein expression was found when compared to young rats. But, in young female rats treated with a synthetic estrogen (Diethylstylbestrol, 20 mg) PTTG protein expression was enhanced (P = 0.029). Therefore, in the three experimental models of prolactinomas, pituitary size was increased and there was hyperprolactinemia, but PTTG levels followed different patterns. Patients with macroprolactinomas were divided in those in which dopaminergic therapy normalized or failed to normalize prolactin levels (responsive and resistant, respectively). When pituitary pttg mRNA level was analyzed in these macroprolactinomas, no differences were found. We next analyzed estrogen action at the pituitary by measuring pituitary estrogen receptor α levels. The D2R knockout female mice have low estrogen levels and in accordance, pituitary estrogen receptors were increased (P = 0.047). On the other hand, in senescent rats estrogen levels were slightly though not significantly higher, and estrogen receptors were similar between groups. The estrogen-treated rats had high pharmacological levels of the synthetic estrogen, and estrogen receptors were markedly lower than in controls (P < 0.0001). Finally, in patients with dopamine resistant or responsive prolactinomas no significant differences in estrogen receptor α levels were found. Therefore, pituitary PTTG was increased only if estrogen action was increased, which correlated with a decrease in pituitary estrogen receptor level. Conclusion We conclude that PTTG does not correlate with prolactin levels or tumor size in animal models of prolactinoma, and its pituitary content is not related to a decrease in dopaminergic control of the lactotrope, but may be influenced by estrogen action at the pituitary level. Therefore it is increased only in prolactinomas generated by estrogen treatment, and not in prolactinomas arising from deficient dopamine control, or in dopamine resistant compared with dopamine responsive human prolactinomas. These results are important in the search for reliable prognostic indicators for patients with pituitary adenomas which will make tumor-specific therapy possible, and help to elucidate the poorly understood phenomenon of pituitary tumorigenesis.


  • Presence of binucleate neurons in the spinal cord of young and senile rats

    by Enrique Leo Portiansky, Claudio Gustavo Barbeito, Mirta Alicia Flamini, Eduardo Juan Gimeno, Rodolfo Gustavo Goya

    The presence of binucleate cells constitutes a normal feature of some animal tissues but is rare in the normal brain and has not been documented in the spinal cord. We assessed different segments of the rat spinal cord in order to determine the frequency and distribution of binucleate neurons in this structure as well as the impact of aging on this neuronal population. Young (4-5 months) and senile (32 months) female Sprague-Dawley rats were used. Sections from cervical, thoracic and lumbar segments were histochemically and immunohistochemically (NeuN) stained and the frequency and distribution of binucleate neurons was determined by manual counting. The frequency of binucleate neurons in all of the analysed segments was comparable between young and senile animals. Binucleate neurons were particularly frequent in the C5 and C6 segments. The overall distribution of binucleate neurons in the different laminae assessed was, Lm-III = 19%; Lm-VI = 17%; Lm-VII = 39%; LmVIII = 8%; Lm-IX = 11%; Lm-X = 6%, and was comparable between young and senile rats. We conclude that binucleate neurons occur as a normal feature of the rat spinal cord and that their frequency and distribution does not change with aging.


  • Partial prevention of hepatic lipid alterations in nude mice by neonatal thymulin gene therapy

    by Margarita M. García de Bravo, Mónica P. Polo, Paula C. Reggiani, Omar J. Rimoldi, Mireille Dardenne, Rodolfo G. Goya

    During adult life athymic (nude) male mice display not only a severe T‐cell‐related immunodeficiency but also endocrine imbalances and a moderate hyperglycemia. We studied the impact of congential athymia on hepatic lipid composition and also assessed the ability of neonatal thymulin gene therapy to prevent the effects of athymia. We constructed a recombinant adenoviral vector, RAd‐metFTS, expression a synthetic DNA sequence encoding met‐FTS, an analog of the thymic peptide facteur thymique sérique (FTS), whose Zn‐bound biologically active form is known as thymulin. On postnatal day 1–2 homozygous (nu/nu) nude and heterozygous (nu/+) mice were injected with 108 pfu of RAd‐metFTS or RAd‐βgal (control vector) intramuscularly. The animals were processed at 52 d of age. Serum thymulin, glycemia, hepatic phospholipid FA compostion and free and esterified cholesterol were determined. Adult homozygous male nudes were significantly (P<0.01) hyperglycemic when compared with their heterozygous counterparts (2.04 vs. 1.40 g/L, respectively). The relative percentage of 16∶0, 18∶1n−9, and 18∶1n−7 FA was lower, whereas that of 18∶0, 20∶4n−6, and 22∶6n−3 FA was higher, in hepatic phospholipid (PL) of nu/nu animals as compared with their nu/+ counterparts. Some of these alterations, such as that in the relative content of 22∶6n−3 in liver PL and the unsaturation index, were completely or partially prevented by neonatal thymulin gene therapy. We conclude that the thymus influences lipid metabolism and that thymulin is involved in this modulatory activity.